Kastrup Jens, Mygind Naja D, Qayyum Abbas A, Mathiasen Anders B
Department of Cardiology & Cardiac Catheterization Laboratory 2014, The Heart Centre, Rigshospitalet, University Hospital of Copenhagen and Faculty of Health Sciences, Copenhagen University, Copenhagen, Denmark -
Minerva Cardioangiol. 2016 Jun;64(3):322-9. Epub 2016 Feb 19.
Ischemic heart disease (IHD) is one of the leading causes of death worldwide and is characterized by the formation of atherosclerotic plaques in the coronary arteries reducing the blood supply to the heart muscle causing ischemia. IHD can result in ST-elevation myocardial infarction (STEMI), chronic IHD and heart failure. The patients suffer from chest pain (angina), dyspnea and a reduced quality of life. Common for all these conditions is loss of functional cardiomyocytes and endothelial cells. Stem cell therapy to regenerate injured myocardium is a new treatment option which has gained much interest in the last 10-15 years especially after STEMI. Many preclinical and clinical studies have shown encouraging results but also very diverse clinical outcomes after stem cell treatment. This diversity in results may be explained by different factors, such as cell isolation technique, infarct location, timing and route of delivery, cell dosage, cell type etc. The present review will try to elaborate and clarify the present status for stem cell therapy in STEMI.
缺血性心脏病（IHD）是全球主要死因之一，其特征是冠状动脉中形成动脉粥样硬化斑块，减少了心肌的血液供应，导致局部缺血。缺血性心脏病可导致ST段抬高型心肌梗死（STEMI）、慢性缺血性心脏病和心力衰竭。患者会出现胸痛（心绞痛）、呼吸困难，生活质量下降。所有这些病症的共同之处在于功能性心肌细胞和内皮细胞的丧失。干细胞疗法用于再生受损心肌是一种新的治疗选择，在过去10至15年中受到了广泛关注，尤其是在STEMI之后。许多临床前和临床研究都显示出了令人鼓舞的结果，但干细胞治疗后的临床结果也非常多样。结果的这种多样性可能由不同因素解释，如细胞分离技术、梗死位置、给药时间和途径、细胞剂量、细胞类型等。本综述将试图阐述和阐明干细胞疗法在STEMI中的现状。
